Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy (Q37983730)

26 August 2017

title

Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy (English)

1 reference

26 August 2017

1 reference

1 reference

Nicolò Rigamonti

1

1 reference

26 August 2017

Matteo Bellone

series ordinal

2

1 reference

26 August 2017

publication date

14 February 2012

1 reference

Cancer Immunology, Immunotherapy

26 August 2017

published in

1 reference

26 August 2017

volume

61

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

453-468

1 reference

26 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prostate cancer in men less than the age of 50: a comparison of race and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Does race affect postoperative outcomes in patients with low-risk prostate cancer who undergo radical prostatectomy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Clinical practice. Localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Expanding treatment options for metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prostate cancer as a model for tumour immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Tumor escape mechanisms in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Enhancing the efficacy of cancer vaccines in urologic oncology: new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Creating immune privilege: active local suppression that benefits friends, but protects foes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

21 January 2018

Inflammation and cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Matrix metalloproteinases: regulators of the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Macrophage diversity enhances tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Cancer-related inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Inflammation in prostate carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Peroxiredoxin 1 controls prostate cancer growth through Toll-like receptor 4-dependent regulation of tumor vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prostate cancer in a transgenic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Autochthonous mouse models for prostate cancer: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prostate cancer chemoprevention by silibinin: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Association of pre- and postoperative plasma levels of transforming growth factor beta(1) and interleukin 6 and its soluble receptor with prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

TGF-beta: a master of all T cell trades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

T cell surveillance of oncogene-induced prostate cancer is impeded by T cell-derived TGF-β1 cytokine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Cancer; a biological approach. I. The processes of control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Aids-related malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

A population-based study of skin cancer incidence and prevalence in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Solid cancers after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Stromal gene expression predicts clinical outcome in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Immune infiltration in human tumors: a prognostic factor that should not be ignored

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Therapeutic management of de novo urological malignancy in renal transplant recipients: the experience of the French Department of Urology and Kidney Transplantation from Bordeaux

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Ex vivo expanded human Vgamma9Vdelta2+ gammadelta-T cells mediate innate antitumor activity against human prostate cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded γδTcells: a phase I clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

21 January 2018

The biology of NKT cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Loss of IFN-gamma production by invariant NK T cells in advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Harnessing invariant NKT cells in vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Natural killer cell activity in patients with prostatic carcinoma and its in vivo boosting with bacillus Calmette-Guérin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Current status of immunological therapies for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Immunosurveillance in human non-viral cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Regulatory T cells and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Tumor-specific regulatory T cells in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Regulatory T cells and Foxp3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Th17 cells: positive or negative role in tumor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Human and mouse plasmacytoid dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

FOXO3 programs tumor-associated DCs to become tolerogenic in human and murine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Myeloid-derived suppressor cell heterogeneity and subset definition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

The emerging role of CTLA-4 as an immune attenuator

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Physiologic control of IDO competence in splenic dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Indoleamine 2,3‐dioxygenase (IDO) activity influence tumor growth in the TRAMP prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Possible roles of excess tryptophan metabolites in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

IDO induces expression of a novel tryptophan transporter in mouse and human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Targeting the tumour vasculature: insights from physiological angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

The neovasculature homing motif NGR: more than meets the eye.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Neoadjuvant vaccination provides superior protection against tumor relapse following surgery compared with adjuvant vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Radiotherapy and short-term androgen deprivation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Pretreatment frequency of circulating IL-17+CD4+T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Radical prostatectomy versus watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Cancer risk after renal transplantation in the nordic countries, 1964-1986

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2α but not HIF-1α

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

Concomitant Tumor and Minor Histocompatibility Antigen–Specific Immunity Initiate Rejection and Maintain Remission from Established Spontaneous Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-012-1216-6

10.1007/S00262-012-1216-6

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference